These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20818645)

  • 41. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bias-reduced and separation-proof conditional logistic regression with small or sparse data sets.
    Heinze G; Puhr R
    Stat Med; 2010 Mar; 29(7-8):770-7. PubMed ID: 20213709
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Empirical likelihood inference for the area under the ROC curve.
    Qin G; Zhou XH
    Biometrics; 2006 Jun; 62(2):613-22. PubMed ID: 16918927
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Two-stage designs for phase II cancer trials with ordinal responses.
    Stallard N; Cockey L
    Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sample size planning for phase II trials based on success probabilities for phase III.
    Götte H; Schüler A; Kirchner M; Kieser M
    Pharm Stat; 2015; 14(6):515-24. PubMed ID: 26412484
    [TBL] [Abstract][Full Text] [Related]  

  • 46. One- and two-stage designs for stratified phase II clinical trials.
    London WB; Chang MN
    Stat Med; 2005 Sep; 24(17):2597-611. PubMed ID: 16118809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Eight interval estimators of a common rate ratio under stratified Poisson sampling.
    Lui KJ
    Stat Med; 2004 Apr; 23(8):1283-96. PubMed ID: 15083483
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Exact and approximate unconditional confidence intervals for proportion difference in the presence of incomplete data.
    Tang ML; Ling MH; Tian GL
    Stat Med; 2009 Feb; 28(4):625-41. PubMed ID: 19035467
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Continuous and group sequential conditional probability ratio tests for phase II clinical trials.
    Tan M; Xiong X
    Stat Med; 1996 Oct; 15(19):2037-51. PubMed ID: 8896138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mixtures of prior distributions for predictive Bayesian sample size calculations in clinical trials.
    Brutti P; De Santis F; Gubbiotti S
    Stat Med; 2009 Jul; 28(17):2185-201. PubMed ID: 19462415
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re: Design and endpoints of clinical trials in hepatocellular carcinoma.
    Di Maio M; Daniele B; Gallo C; Perrone F
    J Natl Cancer Inst; 2008 Nov; 100(21):1557; author reply 1557-8. PubMed ID: 18957679
    [No Abstract]   [Full Text] [Related]  

  • 54. A standardization method to adjust for the effect of patient selection in phase II clinical trials.
    Mazumdar M; Fazzari M; Panageas KS
    Stat Med; 2001 Mar; 20(6):883-92. PubMed ID: 11252010
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A comparison of methods for constructing confidence intervals after phase II/III clinical trials.
    Kimani PK; Todd S; Stallard N
    Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Confidence intervals for biomarker-based human immunodeficiency virus incidence estimates and differences using prevalent data.
    Cole SR; Chu H; Brookmeyer R
    Am J Epidemiol; 2007 Jan; 165(1):94-100. PubMed ID: 17056640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A comparison of methods for adaptive treatment selection.
    Friede T; Stallard N
    Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quality of life in clinical cancer trials: experience and perspective of the European Organization for Research and Treatment of Cancer.
    Kiebert GM; Kaasa S
    J Natl Cancer Inst Monogr; 1996; (20):91-5. PubMed ID: 8750477
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.